Sugi Predict

Sugi Predict / Compounds / SCHEMBL7174816

SCHEMBL7174816

SCHEMBL7174816

Cc1cccc(C)c1C(=O)[PH](=O)c1c(Cl)ccc(C(=O)c2ccccc2)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPK14 Q16539 2/20 0.36
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ PDK4 Q16654 1/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ MYC P01106 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ RORC P51449 2/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ PGR P06401 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7179867 0.95 MAPT (0.38) MAPTALDH1A1LMNAGAAMAPK14
SCHEMBL7181100 0.90 TP53 (0.41) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL7175334 0.87 TP53 (0.36) MAPTALDH1A1LMNAPDK1PDK2
SCHEMBL7184121 0.86 MAPT (0.36) MAPTALDH1A1LMNAGAAMAPK14
SCHEMBL7174653 0.86 LMNA (0.38) MAPTALDH1A1LMNAGAAMAPK14
SCHEMBL7177222 0.86 TP53 (0.37) MAPTALDH1A1LMNAGAAMAPK14
SCHEMBL7186467 0.84 MAPT (0.44) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL7182185 0.83 ALDH1A1 (0.38) MAPTALDH1A1LMNAGAAMAPK14
SCHEMBL7181647 0.82 MAPT (0.42) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL7185603 0.82 PDK1 (0.38) MAPTLMNAPDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885ALDH1A1 3416/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885ALDH1A1 3984/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.